Wenbin Shen

The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei

Disclosures:

  • Employment: none
  • Compensation: none
  • Ownership: none
  • Leadership: none

Presentations

Sep 27

2214 - A Phase II Study of Fruquintinib Combined with Tislelizumab and Sequential Radiotherapy for Recurrent or Oligoprogressive Esophageal Squamous Cell Carcinoma
03:00pm - 04:00pm ET
Sep 27

2211 - Efficacy and Safety of Different Dose Patterns in Concurrent Integrated Radiotherapy for Esophageal Cancer: A Multicenter Real-World Study
03:00pm - 04:00pm ET
Sep 27

2212 - Optimal Sequencing of Immune Checkpoint Inhibitors with Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Cohort Study
03:00pm - 04:00pm ET
Sep 27

2213 - Optimizing Postoperative Adjuvant Strategies in Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy: A Multicenter Real-World Study
03:00pm - 04:00pm ET
Sep 29

1151 - Dynamic Hematologic Trajectories and Machine Learning to Predict Survival and Radiotherapy Benefit In Unresectable Esophageal Squamous Cell Carcinoma Receiving Immunotherapy: A Multicenter, Real-World Study
05:05pm - 05:10pm ET